Tokyo Tape
Sign in
← Kawaguchi Chemical Industry

Quarterly report · Q2

4361.TEDINET S100RBST
Period2022-12-01 → 2023-05-31
Filed2023-07-10
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥4.2bn2022-12-01 → 2023-05-31Cons.Net sales
Revenue¥8.4bn2021-12-01 → 2022-11-30Cons.Net sales (5-year summary)
Revenue¥3.9bn2021-12-01 → 2022-05-31Cons.Net sales
Operating income¥156m2022-12-01 → 2023-05-31Cons.Operating income
Operating income¥226m2021-12-01 → 2022-05-31Cons.Operating income
Ordinary income¥156m2022-12-01 → 2023-05-31Cons.Ordinary income
Ordinary income¥303m2021-12-01 → 2022-11-30Cons.Ordinary income loss (5-year summary)
Ordinary income¥235m2021-12-01 → 2022-05-31Cons.Ordinary income
Profit before tax¥155m2022-12-01 → 2023-05-31Cons.Income before income taxes
Profit before tax¥234m2021-12-01 → 2022-05-31Cons.Income before income taxes
Net income (owners)¥121m2022-12-01 → 2023-05-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥219m2021-12-01 → 2022-11-30Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥179m2021-12-01 → 2022-05-31Cons.Profit loss attributable to owners of parent
Net income¥121m2022-12-01 → 2023-05-31Cons.Profit loss
Net income¥179m2021-12-01 → 2022-05-31Cons.Profit loss
Total assets¥8.0bnat 2023-05-31Cons.Assets
Total assets¥8.3bnat 2022-11-30Cons.Assets
Total assets¥7.8bnat 2022-05-31Cons.Total assets (5-year summary)
Total liabilities¥5.5bnat 2023-05-31Cons.Liabilities
Total liabilities¥5.9bnat 2022-11-30Cons.Liabilities
Net assets / equity¥2.5bnat 2023-05-31Cons.Net assets
Net assets / equity¥2.4bnat 2022-11-30Cons.Net assets
Net assets / equity¥2.4bnat 2022-05-31Cons.Net assets (5-year summary)
Cash and deposits¥999mat 2023-05-31Cons.Cash and deposits
Cash and deposits¥911mat 2022-11-30Cons.Cash and deposits
Cash & equivalents¥999mat 2023-05-31Cons.Cash and cash equivalents
Cash & equivalents¥911mat 2022-11-30Cons.Cash and cash equivalents
Cash & equivalents¥984mat 2022-05-31Cons.Cash and cash equivalents
Cash & equivalents¥1.3bnat 2021-11-30dCons.Cash and cash equivalents
Operating cash flow¥223m2022-12-01 → 2023-05-31Cons.Net cash provided by used in operating activities
Operating cash flow−¥21m2021-12-01 → 2022-11-30Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow−¥124m2021-12-01 → 2022-05-31Cons.Net cash provided by used in operating activities
Investing cash flow−¥217m2022-12-01 → 2023-05-31Cons.Net cash provided by used in investment activities
Investing cash flow−¥243m2021-12-01 → 2022-11-30Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥121m2021-12-01 → 2022-05-31Cons.Net cash provided by used in investment activities
Financing cash flow¥80m2022-12-01 → 2023-05-31Cons.Net cash provided by used in financing activities
Financing cash flow−¥162m2021-12-01 → 2022-11-30Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥104m2021-12-01 → 2022-05-31Cons.Net cash provided by used in financing activities
EPS (basic)¥99.172022-12-01 → 2023-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥65.392023-03-01 → 2023-05-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥179.752021-12-01 → 2022-11-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥147.062021-12-01 → 2022-05-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥68.822022-03-01 → 2022-05-31dCons.Basic earnings loss per share (5-year summary)
Equity ratio31.1%at 2023-05-31Cons.Equity to asset ratio (5-year summary)
Equity ratio29.0%at 2022-11-30Cons.Equity to asset ratio (5-year summary)
Equity ratio30.6%at 2022-05-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2022-12-01 → 2023-05-31¥4.2bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2022-12-01 → 2023-05-31¥141m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2022-12-01 → 2023-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2022-12-01 → 2023-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-12-01 → 2023-05-31¥4.2bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-12-01 → 2023-05-31¥156m
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentrevenue external2021-12-01 → 2022-05-31¥3.9bn
jpcrp040300-q2r_E01006-000Pharmaceutical Productsreportable segmentsegment profit2021-12-01 → 2022-05-31¥211m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentrevenue external2021-12-01 → 2022-05-31¥19m
jpcrp040300-q2r_E01006-000Real Estate Leasingreportable segmentsegment profit2021-12-01 → 2022-05-31¥15m
Total Of Reportable Segments And Otherssegment totalrevenue2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-12-01 → 2022-05-31¥3.9bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-12-01 → 2022-05-31¥226m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 469
ItemContextValueUnit
Other nclPrior1YearInstant128773000JPY
Other nclCurrentQuarterInstant139184000JPY
Noncurrent liabilitiesPrior1YearInstant1487760000JPY
Noncurrent liabilitiesCurrentQuarterInstant1044967000JPY
LiabilitiesPrior1YearInstant5910177000JPY
LiabilitiesCurrentQuarterInstant5490149000JPY
Capital stockPrior1YearInstant610000000JPY
Capital stockCurrentQuarterInstant610000000JPY
Capital surplusPrior1YearInstant58437000JPY
Capital surplusCurrentQuarterInstant58437000JPY
Retained earningsPrior1YearInstant1686444000JPY
Retained earningsCurrentQuarterInstant1746303000JPY
Treasury stockPrior1YearInstant-8202000JPY
Treasury stockCurrentQuarterInstant-8202000JPY
Shareholders equityPrior1YearInstant2346679000JPY
Shareholders equityCurrentQuarterInstant2406538000JPY
Valuation difference on available for sale securitiesPrior1YearInstant27233000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant33340000JPY
Foreign currency translation adjustmentPrior1YearInstant37433000JPY
Foreign currency translation adjustmentCurrentQuarterInstant40523000JPY
Valuation and translation adjustmentsPrior1YearInstant64667000JPY
Valuation and translation adjustmentsCurrentQuarterInstant73864000JPY
Net assetsPrior1YearInstant2411347000JPY
Net assetsCurrentQuarterInstant2480403000JPY
Liabilities and net assetsPrior1YearInstant8321524000JPY
Liabilities and net assetsCurrentQuarterInstant7970553000JPY
Net salesPrior1YTDDuration3946010000JPY
Net salesCurrentYTDDuration4206904000JPY
Cost of salesPrior1YTDDuration3148143000JPY
Cost of salesCurrentYTDDuration3491200000JPY
Gross profitPrior1YTDDuration797867000JPY
Gross profitCurrentYTDDuration715704000JPY
Selling general and administrative expensesPrior1YTDDuration571571000JPY
Selling general and administrative expensesCurrentYTDDuration559348000JPY
Operating incomePrior1YTDDuration226296000JPY
Operating incomeCurrentYTDDuration156355000JPY
Interest income noiPrior1YTDDuration1034000JPY
Interest income noiCurrentYTDDuration1216000JPY
Dividends income noiPrior1YTDDuration1246000JPY
Dividends income noiCurrentYTDDuration1371000JPY
Reversal of allowance for doubtful accounts noiPrior1YTDDuration89000JPY
Reversal of allowance for doubtful accounts noiCurrentYTDDuration329000JPY
Foreign exchange gains noiPrior1YTDDuration9057000JPY
Foreign exchange gains noiCurrentYTDDuration24000JPY
Compensation income noiPrior1YTDDuration2384000JPY
Compensation income noiCurrentYTDDuration1763000JPY
Other noiPrior1YTDDuration4212000JPY
Other noiCurrentYTDDuration4105000JPY
Non operating incomePrior1YTDDuration18024000JPY
Non operating incomeCurrentYTDDuration8810000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-11-30pass
balance sheet identityconsolidated 2023-05-31pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-11-30pass
statement vs summary · net assetsconsolidated 2023-05-31pass
statement vs summary · net income attributable to parentconsolidated 2021-12-01/2022-05-31pass
statement vs summary · net income attributable to parentconsolidated 2022-12-01/2023-05-31pass
statement vs summary · operating cash flowconsolidated 2021-12-01/2022-05-31pass
statement vs summary · operating cash flowconsolidated 2022-12-01/2023-05-31pass
statement vs summary · revenueconsolidated 2021-12-01/2022-05-31pass
statement vs summary · revenueconsolidated 2022-12-01/2023-05-31pass
statement vs summary · total assetsconsolidated 2022-11-30pass
statement vs summary · total assetsconsolidated 2023-05-31pass